About: Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial
Creator	Goldbart, Aviv Efrati, Giora Pillar, Golan-Tripto, Lavie, Moran Lior, Carmon Livnat-Levanon, Galit Lubetzky, Ronit Nahum, Amit Spiegel, Ronen
Source	Medline; PMC
abstract	Currently, there are no approved treatments for infants with acute bronchiolitis, the leading cause for hospitalization of infants worldwide, and thus the recommended approach is supportive. Inhaled Nitric oxide (iNO), possesses anti-viral properties, improves oxygenation, and was shown to be safe in infants with respiratory conditions. Hospitalized infants with acute bronchiolitis were therefore recruited to a prospective double-blinded, multi-center, randomized controlled pilot study. They received intermittent high dose iNO (160 ppm) plus oxygen/air for 30 min or oxygen/air alone (control), five times/day, up to 5 days. Sixty-nine infants were enrolled. No difference was observed in frequencies of subjects with at least one Adverse Event (AE) in iNO (44.1%) vs. control (55.9%); neither was Methemoglobin >7% safety threshold. No drug-related serious AEs (SAEs) were reported. Analysis of Per-Protocol population revealed that length of stay (LOS), time to SpO(2) ≥92%, and time to mTal clinical score ≤5 improved by 26.7 ± 12.7 (Welch’s t-test p = 0.04), 20.8 ± 8.9 (p = 0.023), and 14.6 ± 9.1 (p = 0.118) hours, respectively, in the iNO group compared to the control. Overall, high dose iNO (160ppm) was safe, well-tolerated, reduced LOS and showed rapid improvement of oxygen saturation, compared to the standard therapy. Further investigation in larger cohorts is warranted to validate these encouraging efficacy outcomes. (Trial registration: NCT03053388)
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1038/s41598-020-66433-8
bibo:pmid	32541773
has license	cc-by
sha1sum (hex)	5c09c5943c493e103f9fb92d0b6edb17f78dab5e
schema:url	https://doi.org/10.1038/s41598-020-66433-8
resource representing a document's title	Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial
has PubMed Central identifier	PMC7295966
has PubMed identifier	32541773
schema:publication	Sci Rep
resource representing a document's body	covid:5c09c5943c493e103f9fb92d0b6edb17f78dab5e#body_text
is schema:about of	named entity 'Methemoglobin' named entity 'rapid' named entity 'nitric oxide' named entity 'Trial' named entity 'standard' named entity 'safety' named entity 'infants' named entity 'received' named entity 't-test' named entity 'Event' named entity 'time' named entity 'dose' named entity 'iNO' named entity 'observed' named entity 'doi' named entity 'ppm' named entity 'Adverse Event' named entity 'iNO' named entity 'SAEs' named entity 'nitric oxide' named entity 'randomized clinical trial' named entity 'https' named entity 'registration' named entity 'vasodilation' named entity 'rotameter' named entity 'double-blind' named entity '85%' named entity 'iNO' named entity 'coronavirus' named entity 'echocardiography' named entity 'iNO' named entity 'acute bronchiolitis' named entity 'iNO' named entity 'nitrogen dioxide' named entity 'acute bronchiolitis' named entity 'treatment groups' named entity 'bronchiolitis' named entity 'lung' named entity 'ITT' named entity 'tolerability' named entity 'Welch's t-test' named entity 'Broad spectrum' named entity 'CPAP' named entity 'methemoglobinemia' named entity 'laboratory tests' named entity 'summary statistics' named entity 'pediatric' named entity 'SARS' named entity 'iNO' named entity 'oxygen' named entity 'vaccinia virus' named entity 'AEs' named entity 'sample size' named entity 'individual participant data' named entity 'Chi-square test' named entity 'iNO' named entity 'anti-microbial' named entity 'methemoglobin' named entity 'Welch's t-test' named entity 'control group' named entity 'tolerability' named entity 'Vital signs' named entity 'bronchiolitis' named entity 'cystic fibrosis' named entity 'animal models' named entity 'Endogenous' named entity 'treatment group' named entity 'nature.com' named entity 'standard of care' named entity 'iNO' named entity 'placebo' named entity 'lung'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software